ReviewThe Journal of clinical investigation2024
Infantile hemangioma: the common and enigmatic vascular tumor.
Review in The Journal of clinical investigation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Comparative efficacy and safety of pharmacologic, laser, and combination therapies for infantile hemangioma: a systematic review and network meta-analysis with evidence certainty assessment.Frontiers in pharmacology · 2026Pooled it
- Efficacy and safety of oral propranolol and topical timolol in the treatment of infantile hemangioma: a meta-analysis and systematic review.Frontiers in pharmacology · 2024Pooled it
- Efficacy and safety of sirolimus in the treatment of gastrointestinal angiodysplasias.World journal of gastroenterology · 2025Trial
- Population Pharmacokinetics of Topical Timolol Maleate Gel in Healthy Volunteers and Infants With Superficial Infantile Hemangioma.CPT: pharmacometrics & systems pharmacology · 2026Article
- Research Progress on Angiogenesis and Involution Mechanisms of Infantile Hemangioma and Its Regulation by Active Components ofInternational journal of molecular sciences · 2026Review
- Solid Hydrogel Couplants for Skin Superficial Blood Flow Imaging With Super-Resolution Ultrasound.Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine · 2026Article
- Fibroblast adipogenesis restricts hemangioma growth through a PPARγ/Hippo-YAP/TAZ axis that promotes endothelial apoptosis and cell cycle arrest.Cell death discovery · 2026Article
- Combination Therapy With AOPT Intense Pulsed Light (Dual-Band Vascular Filter) and 1064 nm Nd:YAG Laser for Solitary, Superficial Infantile Hemangioma: A Retrospective Study.Journal of cosmetic dermatology · 2026Article
- Pulmonary Aspergillosis in an Infant with Multiple Hepatic Hemangiomas.Children (Basel, Switzerland) · 2026Article
- Immune microenvironment of infantile hemangioma: cellular dynamics, molecular networks, and emerging immunomodulatory strategies.Frontiers in immunology · 2026Review
- Integrative Bioinformatics Analysis and Machine Learning Reveal TSPAN7 Regulates the Involution of Infantile Hemangioma via NK Cells.Clinical, cosmetic and investigational dermatology · 2026Article
- Key cellular subpopulations and mechanisms of propranolol in infantile hemangioma: insights from single-cell omics.Frontiers in medicine · 2026Review
- Diagnostic challenges of giant cervical pilomatrixoma mimicking malignancy: case report and focused literature review.Frontiers in medicine · 2026Article
- Zebrafish model for studying vascular development and vascular-related disease.Frontiers in cell and developmental biology · 2026Review
- Everolimus and Sunitinib potentially work as therapeutic drugs for infantile hemangiomas.Pediatric research · 2025Article
- Clinical features and surgical management of pilomatrixoma in children: a 332-case retrospective study.Pediatric surgery international · 2025Article
- Exploring Nadolol as a Therapeutic Option for Infantile Hemangioma: A Narrative Review.Cureus · 2025Review
- Dynamic serum biomarkers in infantile hemangioma: the role of VEGF-B, AKT, and eNOS in lesion regression.European journal of pediatrics · 2025Article
- PHACE syndrome: looking backward and forward.Orphanet journal of rare diseases · 2025Review
- A novel therapeutic approach to hemangiomas: Combining photothermal therapy and ferroptosis in a microneedle delivery system.Materials today. Bio · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
Abstract
Infantile hemangioma (IH) is a benign vascular tumor that occurs in 5% of newborns. The tumor follows a life cycle of rapid proliferation in infancy, followed by slow involution in childhood. This unique life cycle has attracted the interest of basic and clinical scientists alike as a paradigm for vasculogenesis, angiogenesis, and vascular regression. Unanswered questions persist about the genetic and molecular drivers of the proliferating and involuting phases. The beta blocker propranolol usually accelerates regression of problematic IHs, yet its mechanism of action on vascular proliferation and differentiation is unclear. Some IHs fail to respond to beta blockers and regrow after discontinuation. Side effects occur and long-term sequelae of propranolol treatment are unknown. This poses clinical challenges and raises novel questions about the mechanisms of vascular overgrowth in IH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.